Advancing Understanding, Diagnosis and Monitoring of Thyroid Hormone Action Defects (ADAM-THAD)

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Genetic, Diagnostic test
Study Type: Observational
SUMMARY

The goal of this observational study is to learn about the neurological and cardiological phenotype of patients with resistance to thyroid hormone (RTH) syndromes beta and alpha (RTHß and RTHa) due to dominant negative variants in the genes encoding the thyroid hormone receptors alpha (THRA) and beta (THRB). The main question\[s\] it aims to answer are: * Define frequency and improve early diagnosis for RTH syndromes * Developing tools to accelerate diagnosis of RTH syndromes * Development and validation of monitoring tools Participants, recruited at neonatal screening or from cohorts of patients with unexplained specific neuro-cognitive or cardiovascular phenotypes will be submitted to biochemical and genetic investigations. In addition pluripotent stem cells will be generated from peripheral blood cells of RTHs patients and studied in vitro to understand the molecular mechanisms underlying neurological and cardiovascular consequences. In vitro and clinical data, will be correlated to identify biomarkers for monitoring treatment.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:

• \- biochemical signature suggestive of RTHs syndromes at birth (a) or symptoms suggestive of RTHs syndromes (b) or known diagnosis of RTHs syndromes (c)

Locations
Other Locations
Italy
Department of Endocrine & Metabolic Diseases, San Luca Hospital
RECRUITING
Milan
Istituto Auxologico Italiano IRCCS
RECRUITING
Milan
Contact Information
Primary
Luca Persani, Prof
luca.persani@unimi.it
02619112738
Time Frame
Start Date: 2023-01-01
Estimated Completion Date: 2026-01-31
Participants
Target number of participants: 150
Treatments
RTH Syndromes
Patients with THRA or THRB gene mutations
Sponsors
Leads: Istituto Auxologico Italiano
Collaborators: Federico II University, ASST Fatebenefratelli Sacco

This content was sourced from clinicaltrials.gov